DDInter1610 DDInter1110
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Rivastigmine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Clonidine
Clonidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Rivastigmine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Atropine
Atropine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Rivastigmine {u} (Compound) causes {v} (Side Effect) Coordination abnormal
Coordination abnormal {u} (Side Effect) is caused by {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pentamidine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Rivastigmine {u} (Compound) upregulates {v} (Gene) WRB
WRB {u} (Gene) is upregulated by {v} (Compound) Propylthiouracil
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Rivastigmine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Propylthiouracil
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Rivastigmine {u} (Compound) upregulates {v} (Gene) GHR
GHR {u} (Gene) is upregulated by {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Rivastigmine {u} (Compound) downregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Fluoxetine
Fluoxetine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Rivastigmine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Rivastigmine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Atropine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Rivastigmine (Compound) causes Coordination abnormal (Side Effect) and Coordination abnormal (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pentamidine (Compound) and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Rivastigmine (Compound) upregulates WRB (Gene) and WRB (Gene) is upregulated by Propylthiouracil (Compound) and Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Rivastigmine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Propylthiouracil (Compound) and Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Rivastigmine (Compound) upregulates GHR (Gene) and GHR (Gene) is upregulated by Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Macimorelin
Rivastigmine (Compound) downregulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Fluoxetine (Compound) and Fluoxetine may lead to a major life threatening interaction when taken with Macimorelin